Dear Representatives Pingree and Carter,

On behalf of IDSA’s 12,000 members, including our 27 members in Maine and our 218 members in Georgia, thank you for your leadership in the federal response to antimicrobial resistance (AMR). IDSA is extremely grateful that your efforts, particularly your letter signed by 59 of your colleagues, resulted in increases for AMR programs in the House Appropriations Committee’s Labor, Health, and Human Services (LHHS) appropriation bill, outlined below.

As you know, AMR is rendering lifesaving medicines ineffective thereby jeopardizing medical procedures that rely upon antibiotics. These include cancer chemotherapy, transplantation, caesarian sections, other surgeries, treatment of serious wounds and burns and care of complex patients — such as individuals with COVID-19 who develop secondary infections. Infectious diseases physicians see firsthand the impact of the growing AMR crisis on our patients, communities and public health, and agree that increased efforts are urgently needed to preserve the effectiveness of antibiotics and strengthen the pipeline of new antibiotics. Increased AMR funding in the House Appropriations mark will expand AMR research and strengthen the antibiotic pipeline and would not have been possible without your leadership. Thank you for your steadfast efforts to expand our capacity to combat AMR to better care for our patients and communities.

Sincerely,

Daniel P. McQuillen, MD, FIDSA
President, Infectious Diseases Society of America
AMR program funding in the House LHHS appropriations bill:

- $202 million for the CDC’s Antibiotic Resistance Solutions Initiative, a $20 million increase over FY2022;
- $31 million in funding for the National Healthcare Safety Network at CDC, a $10 million increase over FY2022;
- $50 million in funding for the Advanced Molecular Detection initiative at CDC, a $15 million increase over FY2022;
- $757 million, an increase of $111 million above FY 2022, for the Center for Global Health. This includes $353 million for global health security, a $100 million increase;
- $845 million for the Biomedical Advanced Research and Development Authority, a $100 million increase over FY2022 funding; and,
- $6.642 billion to the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH) a $320 million increase over FY2022, including $560 million for antibiotic resistance research at NIAID, an increase of $20 million over FY2022.